Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Detke, Holland C ^a   McDonnell, David P ^a   Brunner, Elizabeth ^a   Zhao, Fangyi ^a   Sorsaburu, Sebastian ^a   Stefaniak, Victoria J ^a   Corya, Sara A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CAPTOPRIL; ENALAPRIL; ESCITALOPRAM; FLUVOXAMINE; GLIBENCLAMIDE; INSULIN; LONG ACTING DRUG; MAGNESIUM SULFATE; OLANZAPINE; OXAPROZIN; PLACEBO; PROPRANOLOL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; AGGRESSION; AGITATION; AKATHISIA; ARTICLE; ATAXIA; BLOOD ANALYSIS; BLOOD TOXICITY; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DISEASE COURSE; DISORIENTATION; DIZZINESS; DRUG OVERDOSE; DRUG SAFETY; DYSARTHRIA; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MOTOR DYSFUNCTION; MUSCLE CRAMP; OUTCOME ASSESSMENT; POST INJECTION DELIRIUM SEDATION SYNDROME; RESTLESSNESS; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOMNOLENCE; SYMPTOMATOLOGY; UNCONSCIOUSNESS; URINALYSIS; VITAL SIGN; WEAKNESS; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOXICITY; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; METABOLISM; SLEEP; STATISTICS; SYNDROME; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; DELIRIUM; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; OVERDOSE; RISK FACTORS; SCHIZOPHRENIA; SLEEP; SYNDROME; TREATMENT OUTCOME;

EID: 77955294914     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-43     Document Type: Article

References (28)

1. Lauriello J, Lambert T, Andersen SW, Lin DY, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799. 10.4088/JCP.v69n0512, 18452346.
2. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell DP. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189. 10.1176/appi.ajp.2009.07081221, 20008947.
3. European Medicines Agency Assessment report for Zypadhera. 2008, European Medicines Agency., http://www.emea.europa.eu/humandocs/PDFs/EPAR/Zypadhera/H-890-en6.pdf
4. Electronic Medicines Compendium Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. 2009, Electronic Medicines Compendium., http://emc.medicines.org.uk/medicine/21361/SPC/ZYPADHERA
5. McDonnell DP, Detke HC, Kothare P, Johnson J, Stickelmeyer M, Sorsaburu S, Watson SB, Mitchell MI. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 2010, 10:45. 10.1186/1471-244X-10-45, 20537129.
6. Downham TF, Cawley RA, Salley SO, Dal Santo G. Systemic toxic reactions to Procaine Penicillin G. Sex Transm Dis 1978, 5:4-9. 10.1097/00007435-197801000-00002, 417409.
7. Cummings JL, Barritt CF, Horan M. Delusions induced by procaine penicillin: case report and review of the syndrome. Int J Psychiatry Med 1986, 16:163-168.
8. Institute for Safe Medication Practices ISMP medication safety alert: Hazard warning. 1997, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/19970910.asp
9. Institute for Safe Medication Practices ISMP medication safety alert: Many wrongly believe long-acting parenteral penicillins are for intravenous injection. 1999, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/19990630_2.asp
10. Institute for Safe Medication Practices ISMP medication safety alert: Bicillin products: syringe enhancements may help to prevent IV administration. 2004, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/20040506_2.asp
11. Do Carmo de Castro Miranda M, Rozenfeld S, Pacheco de Oliveira S. A systemic review of the non-allergic adverse reactions following benzathine benzylpenicillin injection. J Vasc Bras 2004, 3:253-260.
12. Novocol Pharmaceuticals of Canada, Inc Septocaine with epinephrine [package insert]. 2005, Novocol Pharmaceuticals of Canada, Inc.
13. Institute for Safe Medication Practices ISMP medication safety alert: Action needed to prevent serious tissue injury with IV promethazine. 2006, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp
14. Sen S, Chini EN, Brown MJ. Complications after unintentional intra-arterial injection of drugs: risks, outcomes and management strategies. Mayo Clin Proc 2005, 80:783-795. 10.4065/80.6.783, 15945530.
15. Tang J, Weiter JJ. Branch retinal artery occlusion after injection of a long-acting risperidone preparation. Ann Intern Med 2007, 147:283-284.
16. Kurtz D, Bergstrom R, McDonnell DP, Mitchell M. Pharmacokinetics of multiple doses of olanzapine long-acting injection, an intramuscular formulation of olanzapine, in stabilized patients with schizophrenia [abstract]. Biol Psychiatry 2008, 63(suppl 1):288S.
17. Mamo D, Kapur S, Keshavan M, Laruelle M, Taylor CC, Kothare PA, Barsoum P, McDonnell D. D2 Receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008, 33:298-304. 10.1038/sj.npp.1301409, 17443131.
18. Detke H, McDonnell D, Andersen S, Watson S. Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data [abstract]. European Neuropsychopharmacology 2008, 18(suppl 4):S435.
19. Detke HC, McDonnell DP, Andersen SW, Watson SB. 160-week interim results from an open-label extension trial of olanzapine long-acting injection [abstract]. International Journal of Neuropsychopharmacology 2008, 11(suppl 1):S151.
20. Goldsweig HG, Kapusta M, Schwatz J. Bleeding, salicylates, and prolonged prothrombin time: three case reports and a review of the literature. J Rheumatol 1976, 3:37-42.
21. Weis HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967, 2:495-497. 10.1016/S0140-6736(67)91658-3, 4166411.
22. Weis HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968, 47:2169-2180. 297378, 5675432.
23. Mukamal KJ, Massaro JM, Ault KA, Mittleman MA, Sutherland PA, Lipinska I, Levy D, D'Agostino RB, Tofler GH. Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. Alcohol Clin Exp Res 2005, 29:1906-1912. 10.1097/01.alc.0000183011.86768.61, 16269922.
24. Iber FL, Shamszad M, Miller PA, Jacob R. Vitamin K deficiency in chronic alcoholic males. Alcohol Clin Exp Res 1986, 10:679-681. 10.1111/j.1530-0277.1986.tb05167.x, 3544923.
25. Hart A, Cohen H. Capillary fragility studies in diabetes. Br Med J 1969, 2:89-91. 10.1136/bmj.2.5649.89, 1982846, 5775455.
26. Purushothaman KR, Meerarani P, Moreno PR. Inflammation and neovascularization in diabetic atherosclerosis. Indian J Exp Biol 2007, 45:93-102.
27. Beyea SC, Nicoll LH. Back to basics. Administering IM injections the right way. Am J Nurs 1996, 96:34-35. 10.2307/3464849, 8546185.
28. Workman B. Safe injection techniques. Nurs Stand 1999, 13:47-53.